Important new paper from @neurosurgerynm.bsky.social and several collaborators reveals critical features of the chordoma immune landscape and lays the foundation for chordoma patients to benefit from immunotherapy advances. 🧵 academic.oup.com/neuro-oncolo...

Integrated Immune Profiling of Chordomas Reveals Spatially Organized Niches and Functional Heterogeneity

AbstractBackground. Chordomas are locally aggressive notochordal tumors with no systemic therapy options. As an ultra-rare cancer type, our understanding o

academic.oup.com

monitoring the situation as a shipment of precious chordoma samples from our biobank flys to Melbourne for our collaborators in the Firestein lab at @hudsonresearch.bsky.social ✈️ 🇦🇺

Positive results are celebrated, but we think sharing negative results is important too. In case helpful to anyone, here are compounds we tested in vitro in recent months which didn't show substantial activity as single agents or synergy with known active compounds: figshare.com/authors/Chor...

We’re hiring for a new role on our research team. It'll be an opportunity to advance interesting science, to work in a nimble and empowering environment, and, to make a tangible impact in the lives of patients in urgent need of new treatment options. www.linkedin.com/jobs/view/42...

The TBXT rs2305089 SNP links the benign notochordal cell tumour and chordoma pathsocjournals.onlinelibrary.wiley.com/doi/10.1002/...

The TBXT rs2305089 SNP links the benign notochordal cell tumour and chordoma

The aim of this research was to investigate the pathogenesis of the bone cancer chordoma and the role of the germline rs2305089 SNP in TBXT. Using medical imaging and genotyping studies, we observed ....

pathsocjournals.onlinelibrary.wiley.com

Interesting new challenge similar in spirit to the well known CACHE!!

Chordoma Foundation Labs@cflabsresearch.bsky.social · last yr.

For all the gains AI affords in compound design and discovery, experimental validation still remains a bottleneck. But we're making that part easy for the cancer target TBXT with a suite of biophysical, in vitro and in vivo assay capabilities—plus prizes for potent binders: tbxtchallenge.org

For all the gains AI affords in compound design and discovery, experimental validation still remains a bottleneck. But we're making that part easy for the cancer target TBXT with a suite of biophysical, in vitro and in vivo assay capabilities—plus prizes for potent binders: tbxtchallenge.org

Chemistry World@chemistryworld.com · 2y ago

Will AI revolutionise drug design and discovery? Not the parts that count, says @dereklowe.bsky.social. Biology doesn’t care whether a drug was designed by a human or an algorithm, and there is no AI yet that can competently predict clinical trial outcomes. www.chemistryworld.com/opinion/robo...

📰 Prof Paul Workman, our former CEO, along with his team in our Centre for Cancer Drug Discovery, have made a breakthrough that could lead to new drugs for #chordoma — a rare #BoneCancer that led to the death of his mother. Read more in @theguardian.com ⤵️ www.theguardian.com/science/2025...

British professor makes ‘thrilling’ breakthrough for cancer that killed his mother

Paul Workman has researched untreatable chordoma for years. Now new technology points towards to a potential drug to beat it

theguardian.com

Crucial building blocks for drugging TBXT (brachyury) published by @ox.ac.uk @icr.ac.uk @uncchapelhill.bsky.social team including crystal structure, discovery of ligandable pockets, and compounds that could serve as starting points for inhibitors or degraders www.nature.com/articles/s41...

Structural insights into human brachyury DNA recognition and discovery of progressible binders for cancer therapy - Nature Communications

This study describes structures of the transcription factor brachyury revealing the mechanism of DNA recognition. They identify fragments using X-ray fragment screening and optimize these into potent ...

nature.com

#chemsky & #compchem peeps, we need your help drugging a difficult target: TBXT (brachyury), a transcription factor critical for our disease, chordoma, and implicated in other cancers. We can offer enabling resources, free SPR analysis and now $500K+ in prizes for TBXT ligands: tbxtchallenge.org

#chemsky & #compchem peeps, we need your help drugging a difficult target: TBXT (brachyury), a transcription factor critical for our disease, chordoma, and implicated in other cancers. We can offer enabling resources, free SPR analysis and now $500K+ in prizes for TBXT ligands: tbxtchallenge.org

Our team recently attended the Connective Tissue Oncology Society (CTOS) annual meeting and presented on three areas of ongoing research in the lab: targeting replication stress, biomarkers of EGFR inhibitor sensitivity, and capabilities to enable TBXT (brachyury) drug discovery. 🧵

Chordoma Foundation scientists share results at international sarcoma…

This was Chordoma Foundation Labs' first invited oral presentation at a major professional conference, and our two posters won recognition as best in…

chordomafoundation.org

Nice work from @dkfz.bsky.social defining TBXT regulome.

bioRxivpreprint@biorxivpreprint.bsky.social · 2y ago

Selective targeting of TBXT with DARPins identifies regulatory networks and therapeutic vulnerabilities in chordoma https://www.biorxiv.org/content/10.1101/2024.09.20.614025v1

Building on recent findings that GPX4 is a genetic essentiality in chordoma, we’ve demonstrated that GPX4 inhibition induces ferroptotic cell death, suggesting #ferroptosis susceptibility may be a targetable vulnerability in chordoma. Results now on Figshare: figshare.com/articles/fig...

Confirmed our recent observation of synergism between gemcitabine and ATR inhibition in two additional cell lines, latest data now on Figshare figshare.com/articles/fig...

Chordoma Foundation Labs@cflabsresearch.bsky.social · 2y ago

We're studying replication stress in chordoma, and have recently identified several therapeutic approaches that exploit this vulnerability. Here are 3 new figures we’ve put on Figshare to enable others to build on our findings before they’re published. 👇

We're studying replication stress in chordoma, and have recently identified several therapeutic approaches that exploit this vulnerability. Here are 3 new figures we’ve put on Figshare to enable others to build on our findings before they’re published. 👇

Hi! We're joining @bsky.app from Twitter. Our feed there is at x.com/CFLabsResearch. We're here to share recent developments from our lab and from the broader chordoma research field, as well as to connect with and learn from others with overlapping research interests/expertise.